Key result
Administration of sarpogrelate hydrochloride significantly decreased platelet-derived microparticles, activated platelets, soluble adhesion molecules, and thrombomodulin in patients with diabetes.
Why the study?
Does sarpogrelate hydrochloride reduce platelet-derived microparticles and soluble adhesion molecules in patients with diabetes mellitus?
Observational (n=48)
Does sarpogrelate hydrochloride reduce platelet-derived microparticles and soluble adhesion molecules in patients with diabetes mellitus?
Sarpogrelate hydrochloride significantly reduces platelet activation markers and adhesion molecules in diabetic patients, suggesting potential benefits in reducing endothelial damage and intrinsic coagulation.
Answers are grounded in this paper and cite their sources.
May reduce thrombotic markers in diabetes but should not change practice; leaves open whether benefits extend to clinical outcomes in RCTs.
We measured platelet-derived microparticles, activated platelets, and various adhesion molecules in 48 patients with diabetes mellitus. We also performed a comparative study of these parameters before and after administration of sarpogrelate hydrochloride. The numbers of platelet-derived microparticles and activated platelets were increased significantly in diabetic patients, and CD63-positive platelets were increased in patients with diabetic complications and poorly controlled blood glucose. Soluble adhesion molecules and thrombomodulin were also increased significantly. After administration of sarpogrelate hydrochloride, not only CD62p- and CD63-positive platelets, but also platelet-derived microparticles were decreased significantly. Soluble adhesion molecules and thrombomodulin were also significantly decreased after the treatment. These data suggest that (a) in patients with diabetes, antiplatelet therapy with sarpogrelate hydrochloride is a useful antithrombin therapy because it suppresses the production of intrinsic coagulants by activated platelets; and (b) sarpogrelate hydrochloride decreases endothelial cell damage via adhesion molecules.
No takes yet. Share an insight, caveat, or question.
Shouzu et al. (2000) conducted an observational in Diabetes mellitus (n=48). Sarpogrelate hydrochloride vs. Baseline (before administration) was evaluated on Levels of platelet-derived microparticles, activated platelets, and soluble adhesion molecules. Administration of sarpogrelate hydrochloride significantly decreased platelet-derived microparticles, activated platelets, soluble adhesion molecules, and thrombomodulin in patients with diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: